Endava plc American Depositary Shares (each representing one Class A Ordinary Share)

Endava experienced a significant stock decline of 29.5% after reporting Q1 fiscal 2026 results that missed previous guidance, with sales declining 8.7% year-over-year and management lowering annual performance targets.

US stock futures traded higher on Wednesday, with the S&P 500 and Nasdaq 100 indices turning positive for the year. Analysts noted a bullish signal in the market, with over 60% of S&P 500 components reaching new 20-day highs, which has historically been followed by strong performance.

Law Offices of Howard G. Smith has filed class action lawsuits on behalf of shareholders of Methode Electronics, Endava, Outset Medical, and Sage Therapeutics. The lawsuits allege that the companies made false or misleading statements about their business operations and prospects.

Investors need to pay close attention to Endava (DAVA) stock based on the movements in the options market lately.

Ron Baron's 13F portfolio value decreased from $40.75B to $31.14B this quarter. Click here to read more about BAMCO's holdings and trades for Q2 2022.